CNR1 and non-alcoholic fatty liver: In addition, elevated circulating endocannabinoids may affect liver processes by stimulating de novo fatty acid synthesis and triglyceride accumulation as a first stage to develop long-term nonalcoholic fatty liver, where a role for CB1R has already been shown [35, 36].